Q4 FY26 revenue target of ₹600 crore
Management expects to achieve ₹600 crore revenue in Q4 FY26, up from ₹580 crore in Q3.
IOLCP / guidance tracker
Keep management guidance in view.
IOL Chemicals and Pharmaceuticals · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
FY27 revenue growth of 10-15%
Management guided for 10-15% top-line growth in FY27, driven by pharma and chemicals.
FY27 bottom-line growth of 15-20%
Management expects 15-20% growth in profit after tax for FY27.
EBITDA margin improvement of 1-2% in Q4 FY26
Management expects EBITDA margin to increase by 1-2% in Q4 FY26 compared to Q3.